Samsara BioCapital related stories
All articles and analysis
A2 Biotherapeutics takes in $57 mln Series AA2 Biotherapeutics, a developer of cell therapies for cancer patients, has raised $57 million in Series A funding. The investors included The Column Group, Vida Ventures, Samsara BioCapital and Nextech Invest.
- Nkarta Therapeutics racks up $114 mln Series B
South San Francisco-based Nkarta Therapeutics, a biopharmaceutical company focused on fighting cancer, has raised $114 million in Series B financing. Samsara BioCapital led the round.
- OrbiMed-backed Bellus Health to list on NASDAQ
Laval, Québec-based clinical-stage biopharmaceutical company Bellus Health Inc has filed for a US$60 million public offering and to list on the NASDAQ under the ticker symbol "BLU." Jefferies, Cowen and Guggenheim are serving as lead underwriters. Bellus Health's backers include OrbiMed Advisors LLC, Power Corporation of Canada, Rocabe Investments Inc., New Leaf Venture Partners, First Manhattan Co and Samsara BioCapital.
- Chinook Therapeutics snags Series A
Chinook Therapeutics has raised US$65 million in Series A financing. Versant Ventures led the round with participation from Apple Tree Partners and Samsara BioCapital. Based in Seattle and Vancouver, British Columbia, Chinook is a developer of precision medicines for kidney diseases.
- Chinook Therapeutics secures $86 mln in Series A financing
Chinook Therapeutics, a Vancouver-based developer of precision medicines for kidney disease, has raised about $86 million (US$65 million) in a Series A financing. U.S. life sciences venture capital firm Versant Ventures led the round, with participation from Apple Tree Partners and Samsara BioCapital. Chinook was incubated through Versant's Inception Sciences and seeded by Versant and Apple Tree. Chinook's technology leverages single-cell RNA sequencing, human-derived organoids and new translational models to develop therapeutics with novel mechanisms of action against kidney disease pathways. Led by President and CEO Eric Dobmeier, the company will use the funds raised to advance several programs into clinical trials by 2021.
- ElevateBio racks up $150 mln Series A
Cambridge, Massachusetts-based ElevateBio, a biotech holding company, has secured $150 million in Series A financing. The investors included UBS Oncology Impact Fund, EcoR1 Capital, Redmile Group and Samsara BioCapital.
- Dewpoint Therapeutics raises $60 mln
Dewpoint Therapeutics said Jan. 30 it raised $60 million in Series A funding led by Polaris Partners. Also investing were Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, Alexandria Venture Investments, and Leaps by Bayer. Dewpoint Therapeutics is developing drugging condensates.
Bellus Health closes $35 mln financing led by OrbiMedLaval, Québec-based clinical-stage biopharmaceutical company Bellus Health Inc (TSX: BLU) has secured $35 million in an equity offering. The offering was led by U.S. healthcare investment firm OrbiMed. New Leaf Venture Partners, First Manhattan Co, Samsara BioCapital, Fonds de solidarité FTQ, AppleTree Partners and Amzak Health also participated. OrbiMed Partner Chau Khuong has joined the board. The proceeds will be used to advance the company's lead drug candidate, BLU-5937, for chronic cough. A Phase 2 study will be initiated in mid-2019. Bellus is led by President and CEO Roberto Bellini.
- Velicept Therapeutics picks up $15 mln
Velicept Therapeutics, a clinical stage pharmaceutical company focused on treating urological and gastrointestinal disorders, has raised $15 million in funding. Samsara BioCapital led the round. In conjunction with the funding, Cory Freedland, a principal at Samsara BioCapital, has joined Velicept's board of directors.